Core Viewpoint - 聚石化学 is under investigation by the China Securities Regulatory Commission (CSRC) for information disclosure violations, which may impact its financial performance and investor confidence [2][3] Company Overview - 聚石化学's main business before listing was modified plastics, but it has since expanded into upstream petrochemical materials and fine chemicals, as well as downstream application products [2] - The company has made significant acquisitions, including a 59.06% stake in 龙华化工 for 75.22 million and a 55% stake in 冠臻科技 for 132 million, which have contributed to its current financial struggles [2] Financial Performance - Since 2021, 聚石化学 has spent over 2.5 billion on fixed assets and construction projects, leading to increased debt levels [2] - The company's gross margin has declined from 24.54% before listing to 10.44% in 2024, despite revenue doubling, resulting in a situation of increasing revenue but decreasing profit [2] - In 2024, the company reported a loss of 236 million due to asset impairment and increased depreciation costs [2] Acquisition Issues - The acquisition of 冠臻科技 at a tenfold premium during the COVID-19 pandemic has led to significant goodwill and asset impairments, with a performance compensation of 60 million that is unlikely to be fully recoverable [4][6] - The performance commitment completion rate for 冠臻科技 in 2023 was -124.82%, indicating severe underperformance [6] Regulatory and Compliance Concerns - The company received a warning letter regarding its 2022 annual report audit, highlighting issues with the audit process [6] - There are concerns about the timing of asset impairment evaluations and whether they comply with accounting standards [6] Market Conditions - The market for protective clothing and related materials has become oversaturated post-pandemic, leading to intensified competition and reduced business for 冠臻科技 [6] - Despite the current challenges, the chemical industry is capital-intensive, and the company may still have a solid fundamental outlook with future capacity expansions [8]

Core Viewpoint - 聚石化学 is under investigation by the China Securities Regulatory Commission (CSRC) for suspected violations of information disclosure laws, which may impact its stock performance and investor confidence [1] Group 1: Company Financials - 聚石化学's revenue for 2023, 2024, and the first half of 2025 was reported as 3.685 billion yuan, 4.080 billion yuan, and 1.977 billion yuan respectively [3] - The net profit attributable to shareholders for the same periods was 29 million yuan, -236 million yuan, and 3 million yuan, indicating a significant decline in profitability [3] - The net profit excluding non-recurring gains and losses was -25 million yuan, -206 million yuan, and -16 million yuan for 2023, 2024, and the first half of 2025 respectively, showing continuous losses [3] Group 2: Stock Performance and Issuance - 聚石化学 was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on January 25, 2021, with an initial issuance of 23.33 million shares at a price of 36.65 yuan per share [1] - The stock reached a peak price of 59.50 yuan on its first trading day but has since entered a state of decline, currently trading below its initial offering price [1] - The company plans to raise up to 400 million yuan through a private placement of A-shares, with the funds intended for working capital [2] Group 3: Regulatory Actions - 聚石化学 received a notice from the CSRC regarding the investigation into its information disclosure practices, which is based on the Securities Law and the Administrative Penalty Law of the People's Republic of China [1] - The company previously faced scrutiny from the Shanghai Stock Exchange for correcting its earnings forecast, which led to regulatory inquiries [4] - The financial officer of 聚石化学 has been held accountable for the discrepancies in the earnings forecast, and the company has committed to improving its internal controls to prevent future issues [4]

Core Viewpoint - Ju Shi Chemical has been investigated by the China Securities Regulatory Commission (CSRC) for suspected violations of information disclosure laws, following significant adjustments to its financial performance forecasts for 2024 [1][2]. Group 1: Regulatory Actions - On November 21, 2025, Ju Shi Chemical received a notice of investigation from the CSRC due to suspected violations of information disclosure laws [1]. - The investigation is based on the company's financial disclosures and adjustments made in its 2024 annual performance report [1]. Group 2: Financial Performance Adjustments - In the announcement on April 29, 2025, Ju Shi Chemical revised its 2024 financial forecasts, reporting a corrected operating profit of -241 million yuan, a decrease of 76.99% [1]. - The total profit was adjusted to -242 million yuan, reflecting a decline of 75.52%, while the net profit attributable to shareholders was revised to -236 million yuan, down 64.6% [1]. - The basic earnings per share were adjusted to -1.95 yuan, a reduction of 0.77 yuan or 65.25% from previous estimates [1]. Group 3: Reasons for Financial Adjustments - The discrepancies in the financial data were primarily attributed to underperformance of Guangdong Guanzhen Technology Co., Ltd., which Ju Shi Chemical acquired in 2021, leading to a provision for impairment losses of 43.62 million yuan [2]. - Additional adjustments included a write-off of fixed assets amounting to 11.63 million yuan, impairment losses on intangible assets of 21 million yuan, and impairment losses related to leased fixed assets totaling 21.75 million yuan [2]. Group 4: Market Impact - As of November 21, 2025, Ju Shi Chemical's stock closed at 22.21 yuan per share, with a market capitalization of 2.69 billion yuan [3].

【导读】聚石化学被中国证监会立案，涉嫌信息披露违法违规 中国基金报记者 卢鸰 聚石化学 11 月 21 日晚公告，公司于 2025 年 11 月 21 日收到中国证监会下发的《立案告 知书》，因公司涉嫌信息披露违法违规，根据《中华人民共和国证券法》《中华人民共和国 行政处罚法》等法律法规，中国证监会决定对公司立案。 降幅为 42.19% ；更正后的基本每股收益为 -1.95 元，比修正前减少 0.77 元，降幅为 65.25% 。 聚石化学当时称，此次更正数据差异的主要原因是：公司 2021 年收购的广东冠臻科技有限 公司经营业绩未达预期、未能完成相关业绩承诺，公司对相关的业绩补偿款计提减值损失 4362 万元；对部分固定资产进行费用化处理，影响金额 1163 万元，无形资产计提减值损 失 2100 万元；对公司循环租赁业务相关固定资产计提减值损失 2175 万元。 此后，聚石化学收到上海证券交易所出具的《关于广东聚石化学股份有限公司 2024 年年度 报告的信息披露监管问询函》，被要求逐项说明各个调整事项的计算方式、原因及合理性， 是否符合企业会计准则的相关规定等；并全面自查是否存在其他会计差错和需要追溯调 ...

Group 1 - The core point of the news is that two companies, 聚石化学 and 豪尔赛, are under investigation by the China Securities Regulatory Commission (CSRC) for suspected violations of information disclosure laws [2][3] - 聚石化学 reported a revenue of 2.963 billion yuan for the first three quarters of 2025, a year-on-year decrease of 7.17%, and a net profit attributable to shareholders of 5.7684 million yuan, with a net loss of 24.5322 million yuan after deducting non-recurring gains and losses [2] - 豪尔赛 stated that its business operations are normal and that the investigation will not have a significant impact on its management [3] Group 2 - Next week, 38 stocks will face a total unlock market value of 21.678 billion yuan [4] - 南方航空 will have 804 million shares listed for circulation, with an unlock market value of 5.689 billion yuan [5] - 菲菱科思 will have 22 million shares listed for circulation, with an unlock market value of 1.871 billion yuan [6] Group 3 - Among the 38 stocks facing unlock, 6 stocks have a high unlock ratio exceeding 30%, including 必易微, 吉冈精密, 赛恩斯, and 菲菱科思 [8] - The average stock price of the 38 stocks has decreased by 8.22% since November, with 久其软件 showing the highest increase of 13.74% [9] - 6 stocks with reported losses in the first three quarters include 红太阳, 水发燃气, 中望软件, 生物谷, 久其软件, and 必易微, indicating higher unlock pressure [10]

Group 1 - The core point of the article is that both 聚石化学 (Jushi Chemical) and 豪尔赛 (Haosai) have received notices from the China Securities Regulatory Commission (CSRC) regarding investigations into alleged violations of information disclosure laws [2][4] - Jushi Chemical announced that it received a notice from the CSRC on November 21, 2025, indicating that the company is under investigation for suspected information disclosure violations [2] - The company stated that all its business activities are currently operating normally and it will actively cooperate with the CSRC's investigation while fulfilling its information disclosure obligations [4][6] Group 2 - Haosai also received a notice from the CSRC for suspected violations of information disclosure laws and will cooperate with the investigation [4][6] - The company confirmed that its business operations are proceeding normally and that the investigation will not have a significant impact on its management and operations [6]

Group 1: Shareholding Changes - Company Zhaoyi Innovation announced that several directors and senior management personnel plan to reduce their holdings by a total of 249,000 shares, with specific reductions from the vice chairman and general manager, as well as other vice presidents [1] - Company Super Aerospace announced a stock suspension due to its controlling shareholders planning a significant matter that may lead to a change in control [2] - Company Haosai is under investigation by the China Securities Regulatory Commission (CSRC) for suspected violations of information disclosure laws [5] Group 2: Major Contracts and Projects - Company Dajin Heavy Industry's wholly-owned subsidiary signed a contract worth approximately 1.339 billion yuan for a European offshore wind farm project, which represents 35.41% of the company's audited revenue for 2024 [3] - Company Ruifeng New Materials plans to increase capital by 200 million yuan in a related party to advance a lithium hexafluorophosphate project [6] Group 3: Regulatory Actions - Company Jushi Chemical received a notice from the CSRC regarding an investigation for suspected violations of information disclosure laws [4] - Company Huosai is also under investigation by the CSRC for similar reasons [5] Group 4: Investment and Acquisitions - Company Gao Neng Environment plans to acquire 45.2% equity in three mining companies [7] - Company Aerospace Electric intends to purchase 32% equity in Shenzhen Aerospace Electric Motor System Co., Ltd. through public bidding [8]

2025.11. 21 本文字数：501，阅读时长大约1分钟 来源 | 第一财经、证券时报、公司公告 同日， 豪尔赛（002963） 公告，公司于近日收到中国证监会下发的《立案告知书》，因涉嫌信息 披露违法违规，根据《中华人民共和国证券法》《中华人民共和国行政处罚法》等法律法规，中国证 监会对公司进行立案。 11月21日晚， 聚石化学（688669） 公告称，公司于2025年11月21日收到中国证监会下发的《立 案告知书》，因公司涉嫌信息披露违法违规，中国证监会决定对公司立案。 聚石化学称， 目前公司各项经营活动和业务均正常开展，将积极配合中国证监会的相关工作，并及 时履行信 息披露义务。 第 一 财 经 持 续 追 踪 财 经 热 点 。 若 您 掌 握 公 司 动 态 、 行 业 趋 势 、 金 融 事 件 等 有 价 值 的 线 索 ， 欢 迎 提 供 。 专 用 邮 箱 ： bianjibu@yicai.com （注：我们会对线索进行核实。您的隐私将严格保密。） 推荐阅读 10月新能源新车降价幅度超11% 豪尔赛表示，公司将积极配合中国证监会立案调查工作，并严格按照相关法律法规的规定和监管要求 及时履 ...

聚石化学表示，目前公司各项经营活动和业务均正常开展。立案调查期间，公司将积极配合证监会的相 关工作，并严格按照相关法律法规和监管要求及时履行信息披露义务。 北京商报讯(记者马换换王蔓蕾)11月21日晚间，聚石化学(688669)披露公告称，公司于当日收到证监会 下发的《立案告知书》，因公司涉嫌信息披露违法违规，证监会决定对公司立案。 ...

Group 1 - Daikin Heavy Industries' subsidiary signed a contract worth approximately 1.339 billion yuan for an offshore wind farm project in Europe, accounting for 35.41% of the company's audited revenue for 2024 [1] Group 2 - Zhaoyi Innovation announced that several board members and senior management plan to reduce their holdings by a total of 249,000 shares, due to personal financial needs, with the reduction period set from December 15, 2025, to March 14, 2026 [2] Group 3 - Jushi Chemical received a notice from the China Securities Regulatory Commission regarding an investigation for suspected violations of information disclosure laws, while the company's operations continue normally [3][6] Group 4 - Chaozhuo Aerospace announced a stock suspension due to major matters being planned by its controlling shareholders, which may lead to a change in control [4] Group 5 - Heng Rui Medicine received approval for clinical trials of SHR-1139 injection, a biopharmaceutical with no similar products approved for sale domestically or internationally, with a cumulative R&D investment of approximately 100.13 million yuan [5] Group 6 - Huayou Pharmaceutical's HYP-6589 tablet for treating advanced non-small cell lung cancer received a clinical trial application acceptance notice, with no similar products approved for sale [8] Group 7 - Renfu Pharmaceutical's application for the marketing license of Dexamethasone L-amphetamine capsules was accepted, aimed at treating ADHD, with a cumulative R&D investment of approximately 90 million yuan [10] Group 8 - Huibo Group won a bid for a 1.596 billion yuan project for the restoration of an oil field in Iraq [10]